Can injections alone curb ROP? Retinopathy of prematurity (ROP) is a neovascular retinal disorder and leading cause of childhood blindness, primarily in infants of low birth weight. At the time of BEAT-EOP, laser therapy was the gold standard for treatment of stage 3+ ROP. However, vascular endothelial growth factor (VEGF) inhibitors, including bevacizumab, were often used off-label, with purported benefits. This prospective, multicenter, randomized controlled clinical trial compared intravitreal bevacizumab monotherapy and conventional laser therapy on recurrence rates of ROP in infants with stage 3+ ROP who had zone I or II posterior disease. 143 infants, evaluated at 54 weeks’ postmenstrual age, were included in the primary outcome analyses.
Key Points:
- There was significant reduction in rates of ROP recurrence in infants in the bevacizumab group (6 of 140 eyes, 4%) versus infants in the laser-therapy group (32 of 146 eyes, 22%)
- When segmenting by zone, a significant treatment effect was found for zone I retinopathy of prematurity (P = 0.003) but not for zone II disease (P = 0.27)
This landmark study demonstrated that intravitreal bevacizumab monotherapy provided a significant decrease in zone I disease recurrence in infants with stage 3+ ROP when compared with conventional laser therapy. Such findings dramatically altered the treatment protocol and outcomes for many infants with ROP.
|
|